{"protocolSection": {"identificationModule": {"nctId": "NCT01221285", "orgStudyIdInfo": {"id": "DAIT ICAC-18"}, "secondaryIdInfos": [{"id": "SCITCO", "type": "OTHER", "domain": "NIAID"}], "organization": {"fullName": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "briefTitle": "Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium", "officialTitle": "A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-18)"}, "statusModule": {"statusVerifiedDate": "2014-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09"}, "primaryCompletionDateStruct": {"date": "2011-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-13", "studyFirstSubmitQcDate": "2010-10-13", "studyFirstPostDateStruct": {"date": "2010-10-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-04-24", "resultsFirstSubmitQcDate": "2014-04-24", "resultsFirstPostDateStruct": {"date": "2014-05-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-05", "lastUpdatePostDateStruct": {"date": "2014-06-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "collaborators": [{"name": "Inner-City Asthma Consortium", "class": "NETWORK"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.", "detailedDescription": "Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma."}, "conditionsModule": {"conditions": ["Asthma", "Perennial Allergic Rhinitis"], "keywords": ["Cockroach", "Immunotherapy", "Subcutaneous immunotherapy", "Inner city asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 11, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "German cockroach allergenic extract", "type": "EXPERIMENTAL", "description": "Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.", "interventionNames": ["Biological: German cockroach (Blattella germanica) allergenic extract"]}], "interventions": [{"type": "BIOLOGICAL", "name": "German cockroach (Blattella germanica) allergenic extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.", "armGroupLabels": ["German cockroach allergenic extract"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Reported Treatment-related Adverse Events (AEs)", "description": "Number of non-serious adverse events reported as possibly related, probably related, or definitely related to study participation.", "timeFrame": "Baseline through 6-months of treatment"}, {"measure": "Number of Reported Treatment-related Serious Adverse Events (SAEs)", "description": "Number of SAEs reported as possibly related, probably related, or definitely related to study participation.", "timeFrame": "Baseline through 6-months of treatment"}], "secondaryOutcomes": [{"measure": "Change in German Cockroach-Specific Serum IgE Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin E (IgE) vs. post-baseline German cockroach-specific serum IgE. Numerator is geometric mean post-baseline IgE; denominator is baseline IgE. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "timeFrame": "Baseline through 6-months of treatment"}, {"measure": "Change in German Cockroach-Specific Serum IgG Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "timeFrame": "Baseline through 6-months of treatment"}, {"measure": "Change in German Cockroach-Specific Serum IgG4 Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin subclass 4 (IgG4) vs. post-baseline German cockroach-specific serum IgG4. Numerator is geometric mean post-baseline IgG4; denominator is baseline IgG4. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "timeFrame": "Baseline through 6-months of treatment"}, {"measure": "Change in IgE Fragment Antibody Binding (FAB) Activity (10 Micrograms/mL Cockroach Allergen Extract)", "description": "Outcome is the change in mean IgE fragment antibody binding (FAB) activity, baseline to post-baseline. Serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants were analyzed to determine if treatment inhibits the in-vitro cockroach antigen binding to B-cells after 6-months of treatment with cockroach SCIT, using the per protocol allergenic extract doses. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "timeFrame": "Baseline through 6-months of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have a history of perennial allergic rhinitis, asthma, or both, for a minimum of 1 year before study entry. For those with asthma:\n\n  * a diagnosis of asthma will be defined as a report by the participant that they have had a clinical diagnosis of asthma made by a physician over a year ago\n  * the participant's asthma must be well controlled as defined by:\n  * a forced expiratory volume at one second (FEV1) greater than or equal to 80% predicted value with or without controller medication\n  * albuterol use for no more than 3 days per week in each of the previous 2 weeks for asthma symptoms (not including exercise prophylaxis)\n* Are sensitive to German cockroach (Blattella germanica) as documented by a positive (\\>= 3 mm greater than negative control) skin prick test result and detectable German cockroach specific IgE (\\>=0.35 kUA/L)\n* Have no known contraindications to therapy with glycerinated German (Blattella germanica) cockroach allergenic extract\n* Are willing to sign the written Informed Consent prior to initiation of any study procedure\n\nExclusion Criteria:\n\n* Are pregnant or lactating. Females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception)\n* Are unable to perform spirometry at screening\n* Have an asthma severity classification at recruitment of severe persistent, using the National Asthma Education and Prevention Program (NAEPP) classification, as evidenced by at least one of the following:\n\n  * requires a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid\n  * have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months\n  * have been treated with depot steroids within the last 12 months\n  * have been hospitalized for asthma within the 6 months prior to recruitment\n  * have had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment\n* Do not have access to a phone (needed for scheduling appointments)\n* Have received allergen immunotherapy (SLIT or SCIT) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study. Subjects who only received placebo therapy in the BioCSI protocol (A Biomarker-based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis, ICAC-12, NCT00829985) are eligible to participate in this study\n* Have previously been treated with anti-IgE therapy within 1 year of recruitment\n* Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study\n* Refuse to sign the Epinephrine Auto-injector Training Form\n* Do not primarily speak English\n* Plan to move from the area during the study period\n* Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher as defined in the protocol\n* Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the participant\n* Are using tricyclic antidepressants or beta-adrenergic blocker drugs (either oral or topical route\\[s\\] of administration)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert Wood, MD", "affiliation": "Johns Hopkins University", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Johns Hopkins University School of Medicine", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}]}, "referencesModule": {"references": [{"pmid": "24184147", "type": "RESULT", "citation": "Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, Hershey G, Liu AH, O'Connor GT, Pongracic JA, Zoratti E, Little F, Granada M, Kennedy S, Durham SR, Shamji MH, Busse WW. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin Immunol. 2014 Mar;133(3):846-52.e6. doi: 10.1016/j.jaci.2013.08.047. Epub 2013 Nov 1."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.5", "lowerLimit": "24", "upperLimit": "52"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}]}, {"title": "Participants with Asthma", "description": "Participants who were diagnosed with asthma by a physician for a minimum of 1 year prior to study enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}]}, {"title": "Participants with Perennial Allergic Rhinitis", "description": "Participants reporting sneezing, nasal congestion or runny nose symptoms greater or equal to 3 days per week for 4 or more months in the year preceding study enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "Glycerinated German Cockroach Prick Skin Test Wheal Size", "description": "German cockroach prick skin test wheal size at screening. A measurable wheal when exposed to cockroach allergen extract by prick skin test (as compared to the negative control wheal) is a sign of allergic sensitization (\"allergy\") to cockroach. Higher wheal sizes indicate greater allergic reaction or sensitization.", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.8", "lowerLimit": "3", "upperLimit": "9"}]}]}]}, {"title": "German Cockroach-Specific Serum Immunoglobulin E (IgE) Levels", "description": "German cockroach-specific serum IgE levels at screening.", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "kU/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.8", "lowerLimit": "0.9", "upperLimit": "24.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Reported Treatment-related Adverse Events (AEs)", "description": "Number of non-serious adverse events reported as possibly related, probably related, or definitely related to study participation.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Severe, Definitely", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Severe, Probably", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Severe, Possibly", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Moderate, Definitely", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Moderate , Probably", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Moderate , Possibly", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Mild , Definitely", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Mild Probably", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}]}]}, {"title": "Mild Possibly", "categories": [{"measurements": [{"groupId": "OG000", "value": "99"}]}]}]}, {"type": "PRIMARY", "title": "Number of Reported Treatment-related Serious Adverse Events (SAEs)", "description": "Number of SAEs reported as possibly related, probably related, or definitely related to study participation.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Definitely related", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Probably related", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Possibly related", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change in German Cockroach-Specific Serum IgE Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin E (IgE) vs. post-baseline German cockroach-specific serum IgE. Numerator is geometric mean post-baseline IgE; denominator is baseline IgE. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.1", "lowerLimit": "1.1", "upperLimit": "2.8"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.02", "statisticalMethod": "Fold change", "paramType": "Fold change", "paramValue": "1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.1", "ciUpperLimit": "2.8", "estimateComment": "Numerator is geometric mean post-baseline IgE. Denominator is baseline IgE."}]}, {"type": "SECONDARY", "title": "Change in German Cockroach-Specific Serum IgG Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "0.1", "lowerLimit": "1.8", "upperLimit": "3.4"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Fold change", "paramType": "Fold change", "paramValue": "2.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.8", "ciUpperLimit": "3.4", "estimateComment": "Numerator is geometric mean post-baseline IgG. Denominator is baseline IgG."}]}, {"type": "SECONDARY", "title": "Change in German Cockroach-Specific Serum IgG4 Over Time", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin subclass 4 (IgG4) vs. post-baseline German cockroach-specific serum IgG4. Numerator is geometric mean post-baseline IgG4; denominator is baseline IgG4. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.9", "spread": "0.7", "lowerLimit": "7.5", "upperLimit": "22.5"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Fold Change", "paramType": "Fold change", "paramValue": "12.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.5", "ciUpperLimit": "22.5", "estimateComment": "Numerator is geometric mean post-baseline IgG4. Denominator is baseline IgG4."}]}, {"type": "SECONDARY", "title": "Change in IgE Fragment Antibody Binding (FAB) Activity (10 Micrograms/mL Cockroach Allergen Extract)", "description": "Outcome is the change in mean IgE fragment antibody binding (FAB) activity, baseline to post-baseline. Serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants were analyzed to determine if treatment inhibits the in-vitro cockroach antigen binding to B-cells after 6-months of treatment with cockroach SCIT, using the per protocol allergenic extract doses. This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent antibody binding", "timeFrame": "Baseline through 6-months of treatment", "groups": [{"id": "OG000", "title": "Glycerinated German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-42.8", "spread": "8.3"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Change", "paramType": "Change", "paramValue": "-42.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-59.4", "ciUpperLimit": "-26.2", "estimateComment": "Numerator is geometric mean post-baseline FAB. Denominator is baseline FAB."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Experimental: German Cockroach Allergenic Extract", "description": "Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 ml of extract at a concentration of 1:20 wt/vol.", "seriousNumAffected": 2, "seriousNumAtRisk": 10, "otherNumAffected": 10, "otherNumAtRisk": 10}], "seriousEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}], "otherEvents": [{"term": "Ear pruritus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Eye swelling", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Lacrimation increased", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Lip pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Lip swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Injection site anaesthesia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Injection site eczema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Injection site erosion", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 6, "numAtRisk": 10}]}, {"term": "Injection site haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 53, "numAffected": 9, "numAtRisk": 10}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 43, "numAffected": 9, "numAtRisk": 10}]}, {"term": "Injection site urticaria", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Blood urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 10}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 10}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Wisdom teeth removal", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Associate Director, Clinical Research Operations Program", "organization": "DAIT/NIAID", "email": "DAITClinicalTrialsGov@niaid.nih.gov", "phone": "301-594-7669"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}, {"id": "D000012221", "term": "Rhinitis, Allergic, Perennial"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M15050", "name": "Rhinitis, Allergic, Perennial", "asFound": "Perennial Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M2853", "name": "Immunomodulating Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}